Experimental Pharmacotherapy for Dry Eye Disease: A Review

References

• Craig JP, Nichols KK, Akpek EK, et al. TFOS DEWS II definition and classification report. Ocul Surf. 2017;15(3):276–283. doi:10.1016/j.jtos.2017.05.008
   PubMed Web of Science ®Google Scholar
• Stapleton F, Alves M, Bunya VY, et al. TFOS DEWS II epidemiology report. Ocul Surf. 2017;15(3):334–365. doi:10.1016/j.jtos.2017.05.003
   PubMed Web of Science ®Google Scholar
• Shimazaki J, Goto E, Ono M, Shimmura S, Tsubota K. Meibomian gland dysfunction in patients with Sjogren syndrome. Ophthalmology. 1998;105(8):1485–1488. doi:10.1016/S0161-6420(98)98033-2
   PubMed Web of Science ®Google Scholar
• Lemp MA, Crews LA, Bron AJ, Foulks GN, Sullivan BD. Distribution of aqueous-deficient and evaporative dry eye in a clinic-based patient cohort: a retrospective study. Cornea. 2012;31(5):472–478. doi:10.1097/ICO.0b013e318225415a
   PubMed Web of Science ®Google Scholar
• Stern ME, Schaumburg CS, Pflugfelder SC. Dry eye as a mucosal autoimmune disease. Int Rev Immunol. 2013;32(1):19–41. doi:10.3109/08830185.2012.748052
   PubMed Web of Science ®Google Scholar
• Rieger G. The importance of the precorneal tear film for the quality of optical imaging. Br J Ophthalmol. 1992;76(3):157–158. doi:10.1136/bjo.76.3.157
   PubMed Web of Science ®Google Scholar
• Bron AJ, Tomlinson A, Foulks GN, et al. Rethinking dry eye disease: a perspective on clinical implications. Ocul Surf. 2014;12(2 SUPPL.). doi:10.1016/j.jtos.2014.02.002
   Google Scholar
• Baudouin C, Messmer EM, Aragona P, et al. Revisiting the vicious circle of dry eye disease: a focus on the pathophysiology of meibomian gland dysfunction. Br J Ophthalmol. 2016;100(3):300–306. doi:10.1136/bjophthalmol-2015-307415
   PubMed Web of Science ®Google Scholar
• Zhang X, Vimalin Jeyalatha M, Qu Y, et al. Dry eye management: targeting the ocular surface microenvironment. Int J Mol Sci. 2017;18(7):1398. doi:10.3390/ijms18071398
   PubMed Web of Science ®Google Scholar
• Willcox MDP, Argüeso P, Georgiev GA, et al. TFOS DEWS II tear film report. Ocul Surf. 2017;15(3):366–403. doi:10.1016/j.jtos.2017.03.006
   PubMed Web of Science ®Google Scholar
• Bron AJ, de Paiva CS, Chauhan SK, et al. TFOS DEWS II pathophysiology report. Ocul Surf. 2017;15(3):438–510. doi:10.1016/j.jtos.2017.05.011
   PubMed Web of Science ®Google Scholar
• Lemp MA, Baudouin C, Baum J, et al. The definition and classification of dry eye disease: report of the definition and classification subcommittee of the international dry eye workshop (2007). Ocul Surf. 2007;5:75–92. Ethis Communications, Inc. doi:10.1016/s1542-0124(12)70081-2
   PubMed Web of Science ®Google Scholar
• Periman LM, Perez VL, Saban DR, Lin MC, Neri P. The immunological basis of dry eye disease and current topical treatment options. J Ocul Pharmacol Ther. 2020;36(3):137–146. doi:10.1089/jop.2019.0060
   PubMed Web of Science ®Google Scholar
• Heidari M, Noorizadeh F, Wu K, Inomata T, Mashaghi A. Dry eye disease: emerging approaches to disease analysis and therapy. J Clin Med. 2019;8(9):1439. doi:10.3390/jcm8091439
   PubMed Web of Science ®Google Scholar
• De Paiva CS, Corrales RM, Villarreal AL, et al. Corticosteroid and doxycycline suppress MMP-9 and inflammatory cytokine expression, MAPK activation in the corneal epithelium in experimental dry eye. Exp Eye Res. 2006;83(3):526–535. doi:10.1016/j.exer.2006.02.004
   PubMed Web of Science ®Google Scholar
• Li DQ, Chen Z, Song XJ, Luo L, Pflugfelder SC. Stimulation of matrix metalloproteinases by hyperosmolarity via a JNK pathway in human corneal epithelial cells. Invest Ophthalmol Vis Sci. 2004;45(12):4302–4311. doi:10.1167/iovs.04-0299
   PubMed Web of Science ®Google Scholar
• Li DQ, Luo L, Chen Z, Kim HS, Song XJ, Pflugfelder SC. JNK and ERK MAP kinases mediate induction of IL-1β, TNF-α and IL-8 following hyperosmolar stress in human limbal epithelial cells. Exp Eye Res. 2006;82(4):588–596. doi:10.1016/j.exer.2005.08.019
   PubMed Web of Science ®Google Scholar
• Luo L, Li DQ, Corrales RM, Pflugfelder SC. Hyperosmolar saline is a proinflammatory stress on the mouse ocular surface. Eye Contact Lens. 2005;31(5):186–193. doi:10.1097/01.ICL.0000162759.79740.46
   PubMedGoogle Scholar
• Lee JH, Kim M, Im YS, Choi W, Byeon SH, Lee HK. NFAT5 induction and its role in hyperosmolar stressed human limbal epithelial cells. Invest Ophthalmol Vis Sci. 2008;49(5):1827–1835. doi:10.1167/iovs.07-1142
   PubMed Web of Science ®Google Scholar
• Luo L, Li DQ, Doshi A, Farley W, Corrales RM, Pflugfelder SC. Experimental dry eye stimulates production of inflammatory cytokines and MMP-9 and activates MAPK signaling pathways on the ocular surface. Invest Ophthalmol Vis Sci. 2004;45(12):4293–4301. doi:10.1167/iovs.03-1145
   PubMed Web of Science ®Google Scholar
• Baudouin C. The pathology of dry eye. Surv Ophthalmol. 2001;45(SUPPL. 2):S211–S220. doi:10.1016/S0039-6257(00)00200-9
   PubMed Web of Science ®Google Scholar
• Yeh S, Song XJ, Farley W, Li DQ, Stern ME, Pflugfelder SC. Apoptosis of ocular surface cells in experimentally induced dry eye. Invest Ophthalmol Vis Sci. 2003;44(1):124–129. doi:10.1167/iovs.02-0581
   PubMed Web of Science ®Google Scholar
• Schaumburg CS, Siemasko KF, De Paiva CS, et al. Ocular surface APCs are necessary for autoreactive T cell-mediated experimental autoimmune lacrimal keratoconjunctivitis. J Immunol. 2011;187(7):3653–3662. doi:10.4049/jimmunol.1101442
   PubMed Web of Science ®Google Scholar
• Zhang X, Volpe EA, Gandhi NB, et al. NK cells promote Th-17 mediated corneal barrier disruption in dry eye. PLoS One. 2012;7(5). doi:10.1371/journal.pone.0036822
   Web of Science ®Google Scholar
• Strauss-Albee DM, Horowitz A, Parham P, Blish CA. Coordinated regulation of NK receptor expression in the maturing human immune system. J Immunol. 2014;193(10):4871–4879. doi:10.4049/jimmunol.1401821
   Web of Science ®Google Scholar
• Stevenson W, Chauhan SK, Dana R. Dry eye disease: an immune-mediated ocular surface disorder. Arch Ophthalmol. 2012;130(1):90–100. doi:10.1001/archophthalmol.2011.364
   PubMedGoogle Scholar
• Hamrah P, Liu Y, Zhang Q, Dana MR. Alterations in corneal stromal dendritic cell phenotype and distribution in inflammation. Arch Ophthalmol. 2003;121(8):1132–1140. doi:10.1001/archopht.121.8.1132
   PubMedGoogle Scholar
• El Annan J, Chauhan SK, Ecoiffier T, Zhang Q, Saban DR, Dana R. Characterization of effector T cells in dry eye disease. Invest Ophthalmol Vis Sci. 2009;50(8):3802–3807. doi:10.1167/iovs.08-2417
   PubMed Web of Science ®Google Scholar
• Stern ME, Schaumburg CS, Dana R, Calonge M, Niederkorn JY, Pflugfelder SC. Autoimmunity at the ocular surface: pathogenesis and regulation. Mucosal Immunol. 2010;3(5):425–442. doi:10.1038/mi.2010.26
   PubMed Web of Science ®Google Scholar
• Bron AJ, Yokoi N, Gaffney E, Tiffany JM. Predicted phenotypes of dry eye: proposed consequences of its natural history. Ocul Surf. 2009;7(2):78–92. doi:10.1016/S1542-0124(12)70299-9
   PubMed Web of Science ®Google Scholar
• Barabino S, Chen Y, Chauhan S, Dana R. Ocular surface immunity: homeostatic mechanisms and their disruption in dry eye disease. Prog Retin Eye Res. 2012;31(3):271–285. doi:10.1016/j.preteyeres.2012.02.003
   PubMed Web of Science ®Google Scholar
• Belmonte C, Nichols JJ, Cox SM, et al. TFOS DEWS II pain and sensation report. Ocul Surf. 2017;15(3):404–437. doi:10.1016/j.jtos.2017.05.002
   PubMed Web of Science ®Google Scholar
• Jones L, Downie LE, Korb D, et al. TFOS DEWS II management and therapy report. Ocul Surf. 2017;15(3):575–628. doi:10.1016/j.jtos.2017.05.006
   PubMed Web of Science ®Google Scholar
• Şimşek C, Doğru M, Kojima T, Tsubota K. Current management and treatment of dry eye disease. Turk J Ophthalmol. 2018;48(6):309–313. doi:10.4274/tjo.69320
   PubMedGoogle Scholar
• Rouen PA, White ML. Dry eye disease: prevalence, assessment, and management. Home Healthc. 2018;36(2):74–83. doi:10.1097/NHH.0000000000000652
   PubMedGoogle Scholar
• Lallemand F, Schmitt M, Bourges JL, Gurny R, Benita S, Garrigue JS. Cyclosporine A delivery to the eye: a comprehensive review of academic and industrial efforts. Eur J Pharm Biopharm. 2017;117:14–28. doi:10.1016/j.ejpb.2017.03.006
   PubMed Web of Science ®Google Scholar
• Agarwal P, Craig JP, Rupenthal ID. Formulation considerations for the management of dry eye disease. Pharmaceutics. 2021;13(2):207. doi:10.3390/pharmaceutics13020207
   PubMed Web of Science ®Google Scholar
• Periman LM, Mah FS, Karpecki PM. A review of the mechanism of action of cyclosporine A: the role of cyclosporine a in dry eye disease and recent formulation developments. Clin Ophthalmol. 2020;14:4187–4200. doi:10.2147/OPTH.S279051
   PubMed Web of Science ®Google Scholar
• Solomon A, Dursun D, Liu Z, Xie Y, Macri A, Pflugfelder S. Pro- and anti-inflammatory forms of interleukin-1 in the tear fluid and conjunctiva of patients with dry-eye disease - PubMed. Invest Ophthalmol Vis Sci. 2001;42(10):2283–2292.
   PubMed Web of Science ®Google Scholar
• Yamada J, Zhu S-N, Streilein W, Dana R. Interleukin-1 receptor antagonist therapy and induction of anterior chamber–associated immune deviation–type tolerance after corneal transplantation. Invest Ophthalmol Vis Sci. 2000;41:4203–4208.
   PubMed Web of Science ®Google Scholar
• Keane-Myers A, Miyazaki D, Dekaris I, Ono S, Dana M. Prevention of allergic eye disease by treatment with IL-1 receptor antagonist - PubMed. Invest Ophthalmol Vis Sci. 1999;40(12):3014–3016.
   Web of Science ®Google Scholar
• Yamada J, Dana MR, Sotozono C, Kinoshita S. Local suppression of IL-1 by receptor antagonist in the rat model of corneal alkali injury. Exp Eye Res. 2003;76(2):161–167. doi:10.1016/S0014-4835(02)00293-2
   PubMed Web of Science ®Google Scholar
• Amparo F, Dastjerdi MH, Okanobo A, et al. Topical interleukin 1 receptor antagonist for treatment of dry eye disease: a randomized clinical trial. JAMA Ophthalmol. 2013;131(6):715–723. doi:10.1001/jamaophthalmol.2013.195
   PubMed Web of Science ®Google Scholar
• Hou J, Townson SA, Kovalchin JT, et al. Design of a superior cytokine antagonist for topical ophthalmic use. Proc Natl Acad Sci U S A. 2013;110(10):3913–3918. doi:10.1073/pnas.1217996110
   PubMed Web of Science ®Google Scholar
• Kovalchin J, King B, Masci A, et al. Preclinical development of EBI-005: an IL-1 receptor-1 inhibitor for the topical ocular treatment of ocular surface inflammatory diseases. Eye Contact Lens. 2018;44(3):170–181. doi:10.1097/ICL.0000000000000414
   Web of Science ®Google Scholar
• Joossen C, Baán A, Moreno-Cinos C, et al. A novel serine protease inhibitor as potential treatment for dry eye syndrome and ocular inflammation. Sci Rep. 2020;10(1). doi:10.1038/s41598-020-74159-w
   Web of Science ®Google Scholar
• Joossens J, Ali OM, El-Sayed I, et al. Small, potent, and selective diaryl phosphonate inhibitors for urokinase-type plasminogen activator with in vivo antimetastatic properties. J Med Chem. 2007;50(26):6638–6646. doi:10.1021/jm700962j
   PubMed Web of Science ®Google Scholar
• Ceuleers H, Hanning N, Heirbaut J, et al. Newly developed serine protease inhibitors decrease visceral hypersensitivity in a post-inflammatory rat model for irritable bowel syndrome. Br J Pharmacol. 2018;175(17):3516–3533. doi:10.1111/bph.14396
   Web of Science ®Google Scholar
• Dattoli SD, Baiula M, De Marco R, et al. DS-70, a novel and potent α4 integrin antagonist, is an effective treatment for experimental allergic conjunctivitis in guinea pigs. Br J Pharmacol. 2018;175(20):3891–3910. doi:10.1111/bph.14458
   Web of Science ®Google Scholar
• Qasem AR, Bucolo C, Baiula M, et al. Contribution of α4β1 integrin to the antiallergic effect of levocabastine. Biochem Pharmacol. 2008;76(6):751–762. doi:10.1016/j.bcp.2008.07.007
   PubMed Web of Science ®Google Scholar
• Haber SL, Benson V, Buckway CJ, Gonzales JM, Romanet D, Scholes B. Lifitegrast: a novel drug for patients with dry eye disease. Ther Adv Ophthalmol. 2019;11:2515841419870366. doi:10.1177/2515841419870366
   Web of Science ®Google Scholar
• Donnenfeld ED, Perry HD, Nattis AS, Rosenberg ED. Lifitegrast for the treatment of dry eye disease in adults. Expert Opin Pharmacother. 2017;18(14):1517–1524. doi:10.1080/14656566.2017.1372748
   PubMed Web of Science ®Google Scholar
• Baiula M, Spampinato S, Gentilucci L, Tolomelli A. Novel ligands targeting α4β1 integrin: therapeutic applications and perspectives. Front Chem. 2019;7:489. doi:10.3389/fchem.2019.00489
   PubMed Web of Science ®Google Scholar
• Ecoiffier T, El Annan J, Rashid S, Schaumberg D, Dana R. Modulation of integrin α4 β1 (VLA-4) in dry eye disease. Arch Ophthalmol. 2008;126(12):1695–1699. doi:10.1001/archopht.126.12.1695
   PubMedGoogle Scholar
• Krauss AH, Corrales RM, Pelegrino FSA, Tukler-Henriksson J, Pflugfelder SC, de Paiva CS. Improvement of outcome measures of dry eye by a novel integrin antagonist in the murine desiccating stress model. Invest Ophthalmol Vis Sci. 2015;56(10):5888–5895. doi:10.1167/iovs.15-17249
   Web of Science ®Google Scholar
• Contreras-Ruiz L, Mir FA, Turpie B, Krauss AH, Masli S. Sjögren’s syndrome associated dry eye in a mouse model is ameliorated by topical application of integrin α4 antagonist GW559090. Exp Eye Res. 2016;143:1–8. doi:10.1016/j.exer.2015.10.008
   Web of Science ®Google Scholar
• Hesselink JMK, Chiosi F, Costagliola C. Resolvins and aliamides: lipid autacoids in ophthalmology – what promise do they hold? Drug Des Devel Ther. 2016;10:3133–3141. doi:10.2147/DDDT.S112389
   PubMed Web of Science ®Google Scholar
• Ji RR, Xu ZZ, Strichartz G, Serhan CN. Emerging roles of resolvins in the resolution of inflammation and pain. Trends Neurosci. 2011;34(11):599–609. doi:10.1016/j.tins.2011.08.005
   PubMed Web of Science ®Google Scholar
• Dartt DA, Hodges RR, Li D, Shatos MA, Lashkari K, Serhan CN. Conjunctival goblet cell secretion stimulated by leukotrienes is reduced by resolvins D1 and E1 to promote resolution of inflammation. J Immunol. 2011;186(7):4455–4466. doi:10.4049/jimmunol.1000833
   PubMed Web of Science ®Google Scholar
• Li N, He J, Schwartz CE, Gjorstrup P, Bazan HEP. Resolvin E1 improves tear production and decreases inflammation in a dry eye mouse model. J Ocul Pharmacol Ther. 2010;26(5):431–439. doi:10.1089/jop.2010.0019
   Web of Science ®Google Scholar
• Schwartz CE, Savinainen A, Gjorstrup P. Resolvin analogs with pharmacokinetic properties suitable for topical administration to treat ocular diseases. Invest Ophthalmol Vis Sci. 2008;49(5):3179.
   Google Scholar
• Cholkar K, Gilger BC, Mitra AK. Topical delivery of aqueous micellar resolvin E1 analog (RX-10045). Int J Pharm. 2016;498(1–2):326–334. doi:10.1016/j.ijpharm.2015.12.037
   PubMed Web of Science ®Google Scholar
• Gjorstrup P, Pflugfelder SP, Pangelinan S, De Paiva CS. Resolvins protect against goblet cell loss and reduce corneal epithelial barrier disruption in a murine model of KCS. Invest Ophthalmol Vis Sci. 2008;122.
   Google Scholar
• Li N, He J, Gjorstrup P, Bazan H. The resolvin E1 analogs, RX-10065 and RX-10005 improve tear production and decrease inflammation in a mouse dry eye model. Invest Ophthalmol Vis Sci. 2008;49:121.
   Google Scholar
• Zhang F, Yang H, Pan Z, et al. Dependence of resolvin-induced increases in corneal epithelial cell migration on EGF receptor transactivation. Invest Ophthalmol Vis Sci. 2010;51(11):5601–5609. doi:10.1167/iovs.09-4468
   Web of Science ®Google Scholar
• Downie LE, Ng SM, Lindsley KB, Akpek EK. Omega-3 and omega-6 polyunsaturated fatty acids for dry eye disease. Cochrane Database Syst Rev. 2019;2019(12). doi:10.1002/14651858.CD011016.pub2
   Web of Science ®Google Scholar
• Schmidt TA, Sullivan DA, Knop E, et al. Transcription, translation, and function of lubricin, a boundary lubricant, at the ocular surface. JAMA Ophthalmol. 2013;131(6):766–776. doi:10.1001/jamaophthalmol.2013.2385
   PubMed Web of Science ®Google Scholar
• Lambiase A, Sullivan BD, Schmidt TA, et al. A two-week, randomized, double-masked study to evaluate safety and efficacy of lubricin (150 μg/mL) eye drops versus sodium hyaluronate (HA) 0.18% eye drops (Vismed®) in patients with moderate dry eye disease. Ocul Surf. 2017;15(1):77–87. doi:10.1016/j.jtos.2016.08.004
   PubMed Web of Science ®Google Scholar
• Hou LF, He SJ, Li X, et al. Oral administration of artemisinin analog SM934 ameliorates lupus syndromes in MRL/lpr mice by inhibiting Th1 and Th17 cell responses. Arthritis Rheum. 2011;63(8):2445–2455. doi:10.1002/art.30392
   Web of Science ®Google Scholar
• Yan YX, Shao MJ, Qi Q, et al. Artemisinin analogue SM934 ameliorates DSS-induced mouse ulcerative colitis via suppressing neutrophils and macrophages. Acta Pharmacol Sin. 2018;39(10):1633–1644. doi:10.1038/aps.2017.185
   PubMed Web of Science ®Google Scholar
• Hou LF, He SJ, Li X, et al. Sm934 treated lupus-prone NZB×NZW F 1 mice by enhancing macrophage interleukin-10 production and suppressing pathogenic T cell development. PLoS One. 2012;7(2):e32424. doi:10.1371/journal.pone.0032424
   Web of Science ®Google Scholar
• Yang FM, Fan D, Yang XQ, et al. The artemisinin analog SM934 alleviates dry eye disease in rodent models by regulating TLR4/NF-κB/NLRP3 signaling. Acta Pharmacol Sin. 2020. doi:10.1038/s41401-020-0484-5
   Web of Science ®Google Scholar
• Skulachev VP. Cationic antioxidants as a powerful tool against mitochondrial oxidative stress. Biochem Biophys Res Commun. 2013;441(2):275–279. doi:10.1016/j.bbrc.2013.10.063
   PubMed Web of Science ®Google Scholar
• Wei Y, Troger A, Spahiu V, et al. The role of SKQ1 (Visomitin) in inflammation and wound healing of the ocular surface. Ophthalmol Ther. 2019;8(1):63–73. doi:10.1007/s40123-018-0158-2
   PubMed Web of Science ®Google Scholar
• Zernii EY, Gancharova OS, Baksheeva VE, et al. Mitochondria-targeted antioxidant SkQ1 prevents anesthesia-induced dry eye syndrome. Oxid Med Cell Longev. 2017;2017:1–17. doi:10.1155/2017/9281519
   Web of Science ®Google Scholar
• Voronkova YG, Popova TN, Agarkov AA, Zinovkin RA. Effect of SkQ1 on activity of the glutathione system and NADPH-generating enzymes in an experimental model of hyperglycemia. Biochem. 2015;80(12):1614–1621. doi:10.1134/S000629791512010X
   Web of Science ®Google Scholar
• Brzheskiy VV, Efimova EL, Vorontsova TN, et al. Results of a multicenter, randomized, double-masked, placebo-controlled clinical study of the efficacy and safety of visomitin eye drops in patients with dry eye syndrome. Adv Ther. 2015;32(12):1263–1279. doi:10.1007/s12325-015-0273-6
   PubMed Web of Science ®Google Scholar
• Gutierrez LS, Lopez-Dee Z, Pidcock K. Thrombospondin-1: multiple paths to inflammation. Mediators Inflamm. 2011;2011. doi:10.1155/2011/296069.
   Web of Science ®Google Scholar
• Wight TN, Raugi GJ, Mumby SM, Bornstein P. Light microscopic immunolocation of thrombospondin in human tissues. J Histochem Cytochem. 1985;33(4):295–302. doi:10.1177/33.4.3884704
   Web of Science ®Google Scholar
• Grimbert P, Bouguermouh S, Baba N, et al. Thrombospondin/CD47 interaction: a pathway to generate regulatory T cells from human CD4 + CD25 − T cells in response to inflammation. J Immunol. 2006;177(6):3534–3541. doi:10.4049/jimmunol.177.6.3534
   Web of Science ®Google Scholar
• Doyen V, Rubio M, Braun D, et al. Thrombospondin 1 is an autocrine negative regulator of human dendritic cell activation. J Exp Med. 2003;198(8):1277–1283. doi:10.1084/jem.20030705
   Web of Science ®Google Scholar
• Jiménez B, Volpert OV, Crawford SE, Febbraio M, Silverstein RL, Bouck N. Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1. Nat Med. 2000;6(1):41–48. doi:10.1038/71517
   PubMed Web of Science ®Google Scholar
• Saban DR, Bock F, Chauhan SK, Masli S, Dana R. Thrombospondin-1 derived from APCs regulates their capacity for allosensitization. J Immunol. 2010;185(8):4691–4697. doi:10.4049/jimmunol.1001133
   Web of Science ®Google Scholar
• Sekiyama E, Nakamura T, Cooper LJ, et al. Unique distribution of thrombospondin-1 in human ocular surface epithelium. Invest Ophthalmol Vis Sci. 2006;47(4):1352–1358. doi:10.1167/iovs.05-1305
   Web of Science ®Google Scholar
• Anshoo C, Paul H, Hart Charles A, Kaye Stephen B, Mark B, Ian G. Suppression of thrombospondin 1 and 2 production by herpes simplex virus 1 infection in cultured keratocytes - PubMed. Mol Vis. 2005;11:163–168.
   Web of Science ®Google Scholar
• Scheef EA, Huang Q, Wang S, Sorenson CM, Sheibani N. Isolation and characterization of corneal endothelial cells from wild type and thrombospondin-1 deficient mice. Mol Vis. 2007;13:1483–1495.
   PubMed Web of Science ®Google Scholar
• Turpie B, Yoshimura T, Gulati A, Rios JD, Dartt DA, Masli S. Sjögren’s syndrome-like ocular surface disease in thrombospondin-1 deficient mice. Am J Pathol. 2009;175(3):1136–1147. doi:10.2353/ajpath.2009.081058
   PubMed Web of Science ®Google Scholar
• Tan X, Chen Y, Foulsham W, et al. The immunoregulatory role of corneal epithelium-derived thrombospondin-1 in dry eye disease. Ocul Surf. 2018;16(4):470–477. doi:10.1016/j.jtos.2018.07.005
   Web of Science ®Google Scholar
• Ruiz-Ederra J, Levin MH, Verkman AS. In situ fluorescence measurement of tear film [Na+], [K+], [Cl-], and pH in mice shows marked hypertonicity in aquaporin-5 deficiency. Invest Ophthalmol Vis Sci. 2009;50(5):2132–2138. doi:10.1167/iovs.08-3033
   Web of Science ®Google Scholar
• Levin MH, Jung KK, Hu J, Verkman AS. Potential difference measurements of ocular surface Na+ absorption analyzed using an electrokinetic model. Invest Ophthalmol Vis Sci. 2006;47(1):306–316. doi:10.1167/iovs.05-1082
   PubMed Web of Science ®Google Scholar
• Levin MH, Verkman AS. CFTR-regulated chloride transport at the ocular surface in living mice measured by potential differences. Invest Ophthalmol Vis Sci. 2005;46(4):1428–1434. doi:10.1167/iovs.04-1314
   PubMed Web of Science ®Google Scholar
• Hara S, Hazama A, Miyake M, et al. The effect of topical amiloride eye drops on tear quantity in rabbits - PubMed. Mol Vis. 2010;16:2279–2285.
   PubMed Web of Science ®Google Scholar
• Mirshahi M, Nicolas C, Mirshahi S, Golestaneh N, D’Hermies F, Agarwal MK. Immunochemical analysis of the sodium channel in rodent and human eye. Exp Eye Res. 1999;69(1):21–32. doi:10.1006/exer.1999.0675
   Web of Science ®Google Scholar
• Thelin WR, Johnson MR, Hirsh AJ, Kublin CL, Zoukhri D. Effect of topically applied epithelial sodium channel inhibitors on tear production in normal mice and in mice with induced aqueous tear deficiency. J Ocul Pharmacol Ther. 2012;28(4):433–438. doi:10.1089/jop.2011.0157
   PubMed Web of Science ®Google Scholar
• Boyer J, Johnson MR, Ansede J, Donn K, Boucher R, Thelin W. P-321, a novel long-acting epithelial sodium channel (ENaC) blocker for the treatment of dry eye disease. Invest Ophthalmol Vis Sci. 2013;54(15):957.
   Web of Science ®Google Scholar
• Yang JM, Wei ET, Kim SJ, Yoon KC. TRPM8 channels and dry eye. Pharmaceuticals. 2018;11(4):125. doi:10.3390/ph11040125
   Web of Science ®Google Scholar
• González-Muñiz R, Bonache MA, Martín-Escura C, Gómez-Monterrey I. Recent progress in TRPM8 modulation: an update. Int J Mol Sci. 2019;20(11):2618. doi:10.3390/ijms20112618
   Web of Science ®Google Scholar
• Bharate SS, Bharate SB. Modulation of thermoreceptor TRPM8 by cooling compounds. ACS Chem Neurosci. 2012;3(4):248–267. doi:10.1021/cn300006u
   PubMed Web of Science ®Google Scholar
• Sherkheli MA, Vogt-Eisele AK, Bura D, Beltrán Márques LR, Gisselmann G, Hatt H. Characterization of selective trpm8 l igands and their structure activity response (S.A.R) relationship. J Pharm Pharm Sci. 2010;13(2):242–253. doi:10.18433/j3n88n
   PubMed Web of Science ®Google Scholar
• Parra A, Madrid R, Echevarria D, et al. Ocular surface wetness is regulated by TRPM8-dependent cold thermoreceptors of the cornea. Nat Med. 2010;16(12):1396–1399. doi:10.1038/nm.2264
   PubMed Web of Science ®Google Scholar
• Chen G-L, Lei M, Zhou L-P, Zeng B, Zou F, Xu S-Z. Borneol is a TRPM8 agonist that increases ocular surface wetness. PLoS One. 2016;11(7):e0158868. doi:10.1371/journal.pone.0158868
   Web of Science ®Google Scholar
• Yang JM, Li F, Liu Q, et al. A novel TRPM8 agonist relieves dry eye discomfort. BMC Ophthalmol. 2017;17(1). doi:10.1186/s12886-017-0495-2
   Web of Science ®Google Scholar
• Yoon HJ, Kim J, Yang JM, Wei ET, Kim SJ, Yoon KC. Topical TRPM8 agonist for relieving neuropathic ocular pain in patients with dry eye: a pilot study. J Clin Med. 2021;10(2):250. doi:10.3390/jcm10020250
   Web of Science ®Google Scholar
• Yin Y, Le SC, Hsu AL, Borgnia MJ, Yang H, Lee SY. Structural basis of cooling agent and lipid sensing by the cold-activated TRPM8 channel. Science. 2019;363(6430):eaav9334. doi:10.1126/science.aav9334
   PubMed Web of Science ®Google Scholar
• Rodríguez-Arévalo S, Pujol E, Abás S, Galdeano C, Escolano C, Vázquez S. Synthesis, characterization and HPLC analysis of the (1S,2S,5R)-diastereomer and the enantiomer of the clinical candidate AR-15512. Molecules. 2021;26(4):906. doi:10.3390/molecules26040906
   Web of Science ®Google Scholar
• Moreno-Montañés J, Bleau AM, Jimenez AI. Tivanisiran, a novel siRNA for the treatment of dry eye disease. Expert Opin Investig Drugs. 2018;27(4):421–426. doi:10.1080/13543784.2018.1457647
   PubMed Web of Science ®Google Scholar
• Bourinet E, Altier C, Hildebrand ME, Trang T, Salter MW, Zamponi GW. Calcium-permeable ion channels in pain signaling. Physiol Rev. 2014;94(1):81–140. doi:10.1152/physrev.00023.2013
   PubMed Web of Science ®Google Scholar
• Gonzalez G, Garcia de la Rubia P, Gallar J, Belmonte C. Reduction of capsaicin-induced ocular pain and neurogenic inflammation by calcium antagonists. Invest Ophthalmol Vis Sci. 1993;34(12):3329–3335.
   Web of Science ®Google Scholar
• Benitez-Del-Castillo JM, Moreno-Montañés J, Jiménez-Alfaro I, et al. Safety and efficacy clinical trials for SYL1001, a novel short interfering RNA for the treatment of dry eye disease. Invest Ophthalmol Vis Sci. 2016;57(14):6447–6454. doi:10.1167/iovs.16-20303
   PubMed Web of Science ®Google Scholar
• Giannaccare G, Carnevali A, Senni C, Logozzo L, Scorcia V. Umbilical cord blood and serum for the treatment of ocular diseases: a comprehensive review. Ophthalmol Ther. 2020;9(2):235–248. doi:10.1007/s40123-020-00239-9
   PubMed Web of Science ®Google Scholar
• Soni NG, Jeng BH. Blood-derived topical therapy for ocular surface diseases. Br J Ophthalmol. 2016;100(1):22–27. doi:10.1136/bjophthalmol-2015-306842
   PubMed Web of Science ®Google Scholar
• Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in health and disease. Nat Rev Immunol. 2008;8(9):726–736. doi:10.1038/nri2395
   PubMed Web of Science ®Google Scholar
• Lu X, Li N, Zhao L, et al. Human umbilical cord mesenchymal stem cells alleviate ongoing autoimmune dacryoadenitis in rabbits via polarizing macrophages into an anti-inflammatory phenotype. Exp Eye Res. 2020;191:107905. doi:10.1016/j.exer.2019.107905
   Web of Science ®Google Scholar
• Lee MJ, Ko AY, Ko JH, et al. Mesenchymal stem/stromal cells protect the ocular surface by suppressing inflammation in an experimental dry eye. Mol Ther. 2015;23(1):139–146. doi:10.1038/mt.2014.159
   PubMed Web of Science ®Google Scholar
• Weng J, He C, Lai P, et al. Mesenchymal stromal cells treatment attenuates dry eye in patients with chronic graft-versus-host disease. Mol Ther. 2012;20(12):2347–2354. doi:10.1038/mt.2012.208
   PubMed Web of Science ®Google Scholar
• Sáles CS, Johnston LJ, Ta CN. Long-term clinical course of dry eye in patients with chronic graft-versus-host disease referred for eye examination. Cornea. 2011;30(2):143–149. doi:10.1097/ICO.0b013e3181e9b3bf
   PubMed Web of Science ®Google Scholar